Risk fo Bacterial Meningitis in Children with Cochlear Implants
NEJM 349:435-445, 421, Reefhuis,J.,et al, 2003
Brain Abscess after Endovascular Coiling of Saccular Aneurysm: Case Report
AJNR 23:697-699, AL-Okaili,R. &Patel,S.J., 2002
Infection Related to Intracranial Pressure Monitors in Adults: Analysis of Risk Factors and Antibiotic Prophylaxis
JNNP 69:381-384, Rebuck,J.A. et al, 2000
Drugs and Myasthenia Gravis, An Update
Arch Int Med 157:399-408, Wittbrodt,E.T., 1997
Drug-Induced Neurologic Disorders in Childhood
Current Problems in Pediatrics 1:1, Schwartz,J., 1971
Vitamin B12 Deficiency:NICE Guideline Summary
BMJ 385:q1019, q1262, Sands,T.,et al, 2024
ANA Investigates: Neurological Complications of Covid-19 Vaccines
Ann Neurol 89:856-857, Goss, A.L.,et al, 2021
Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020
Hemophagocytic Lymphohistiocytosis Associated with the Use of Lamotrigine
Neurol 92:e2401-e2405, Kim, T.,et al, 2019
Dupuytren, Ledderhose, and Peyronie Diseases after Primidone Use for Essential Tremor
Neurologist 24:150-151, Felipe, L.,et al, 2019
Maternal and Fetal Risks of Natalizumab Exposure in Utero
Neurol 90:443-444, Marrie, R.A.,et al, 2018
Hemophagocytic Lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab
Neurol 90:849-851, Saarela, M.,et al, 2018
Myasthenia Gravis Following Alemtuzumab Therapy for Multiple Sclerosis
Neurol 91:622-624, Midaglia, L.,et al, 2018
Five Cases of Malignant Melanoma During Fingolimod Treatment in Dutch Patients with MS
Neurol 89:970-972, Killestein, J.,et al, 2017
Clinicopathologic Conference, Copper Deficiency Myelopathy
NEJM 377:1977-1984, Case 35-2017, 2017
Antibiotic-Associated Encephalopathy
Neurol 86:963-971, Bhattacharyya, S.,et al, 2016
Metronidazole-Associated Encephalopathy
NEJM 374:1465, Baden, L.R., 2016
Fulminant Central Nervous System Nocardiosis in a Patient Treated with Alemtuzumab for Relapsing-Remitting Multiple Sclerosis
JAMA Neurol 73:757-759, Penkert, H.,et al, 2016
Seizures as Adverse Events of Antibiotic Drugs
Neurol 85:1332-1341, Sutter, R.,et al, 2015
Serotonin Syndrome
BMJ 348:g1626, Buckley, N.A.,et al, 2014
Oral Fluoroquinolone Use and Risk of Peripheral Neuropathy
Neurol 83:1261-1263, Etminan, M.,et al, 2014
Retrospective Review of Cerebral Mycotic Aneurysms in 26 Patients: Focus on Treatment in Strongly Immunocompromised Patients with a Brief Literature Review
AJNR 34:823-827, Allen, L.M.,et al, 2013
Association between Guillain-Barr� Syndrome and Influenza a (H1N1) 2009 Monovalent Inactivated Vaccines in the USA: A Meta-Analysis
Lancet 381:1461-1468, Salmon, D.,et al, 2013
Summary of Evidence-Based Guideline: Periprocedural Management of Antithrombic Medications in Patients with Ischemic Cerebrovascular Disease
Neurol 80:2065-2069, Armstrong, M.,et al, 2013
Left Atrial Catheter Ablation and Ischemic Stroke
Stroke 43:265-270, Haeusler, K.G.,et al, 2012
Fingolimod-Associated Macular Edema
Neurol 78:672-680, Jain,N. and Bhatti,M.T., 2012
Clinicopathologic Conference,Necrotizing Noninflammatory Myopathy Consistent with Exposure to Statins
NEJM 36:944-954, Case 7-2012, 2012
Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
NEJM 366:1870-1880,1938, Bloomgren, G.,et al, 2012
Tumefactive Multiple Sclerosis Lesions under Fingolimod Treatment
Neurol 79:2000-2002,1942, Visser, F.,et al, 2012
Severe Relapses under Fingolimod Treatment Prescribed after Natalizumab
Neurol 79:2004-2006,1942, Centonze, D.,et al, 2012
Multiple Sclerosis Rebound Following Herpes Zoster Infection and Suspension of Fingolimod
Neurol 79:2006-2007,1942, Gross, C.M.,et al, 2012
Management of Anticoagulation Before and After Elective Surgery
www.uptodate.com Dec. 2012, Lip, G. & Douketis, J., 2012
Withdrawal of Antithrombotic Agents and Its Impact on Ischemic Stroke Occurence
Stroke 42:2509-2514, Broderick, J.,et al, 2011
Postvaccination Miller Fisher Syndrome
Arch Neurol 68:1325-1327, Shoamanesh, A.,et al, 2011
Management and Outcome of CSF-JC Virus PCR-negative PML in a Natalizumab-treated Patient with MS
Neurol 77:2010-2016, Kuhle, J.,et al, 2011
Lamotrigine: An Unusual Etiology for Aseptic Meningitis
Neurologist 16:35-36, Lam,G.,et al, 2010
Severe Cutaneous Candida Infection During Natalizumab Therapy in Multiple Sclerosis
Neurol 74:521-523, Gutwinski,S.,et al, 2010
Nosocomial Bacterial Meningitis
NEJM 362:146-154, van de Beek,D.,et al, 2010
Natalizumab and Progressive Multifocal Leukoencephalopathy: What are the Causal Factors and Can It be Avoided?
Arch Neurol 67:923-930, Warnke,C., et al, 2010
Longitudinally Extensive Transverse Myelitis Following Vaccination With Nasal Attenuated Novel Influenza A (H1N1) Vaccine
Arch Neurol 67:1018-1020, Akkad,W., et al, 2010
Cardiotoxicity and Other Adverse Events Associated With Mitoxantrone Treatment for MS
Neurol 74:1822-1826, Kingwell,E., et al, 2010
Polytherapy Increases the Risk of Infertility in Women With Epilepsy
Neurol 75:1351-1355, 1316, Sukumaran,S.C.,et al, 2010
Progressive Multifocal Leukoencephalopathy: Can We Reduce Risk in Patients Receiving Biological Immunomodulatory Therapies?
Ann Neurol 68:271-274, Tyler,K., 2010
Intrauterine Exposure to Carbamazepine and Specific Congenital Malformations: Systematic Review and Case-Control Study
BMJ 341:c6581, 1229, Jentik,J.,et al, 2010
Multiple Sclerosis Therapeutics: Unexpected Outcomes Clouding Undisputed Successes
Neurol 72:1008-1015, Wiendl,H. &Hohlfeld,R., 2009
Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation
NEJM 360:2066-2078,2127, The ACTIVE Investigators, 2009
Opportunistic Infections and Other Risks with Newer Multiple Sclerosis Therapies
Ann Neurol 65:367-377, Berger,J.R. &Houff,S., 2009
Severe Cardiac Failure in a Patient with Multiple Sclerosis Following Low-Dose Mitoxantrone Treatment
Neurol 73:991-993, D�rr,J.,et al, 2009
Progressive Multifocal Leukoencephalopathy After Natalizumab Monotherapy
NEJM 361:1081-1087, Linda,H.,et al, 2009